These findings reveal a critical link between genetic risk, lncRNAs, cancer immunosurveillance and breast tumorigenesis, positioning BRRIAR as a promising lncRNA-based RIG-I activator for ER + breast cancer therapy. The gene discussed is ESR1; the disease is breast carcinoma.